MOTS-c and Bupropion Interaction: Safety, Risks, and Clinical Guidance

Why This Combination Raises Questions

Patients using bupropion for depression, smoking cessation, or weight management increasingly encounter MOTS-c in longevity and metabolic optimization contexts. The question is reasonable: bupropion carries a boxed warning about seizure risk and inhibits CYP2D6, while MOTS-c is a relatively novel peptide with limited human pharmacology data.

MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) was first characterized in 2015 by Lee et al. At the University of Southern California, who demonstrated that this 16-amino-acid peptide activates AMPK and improves insulin sensitivity in mouse models of diet-induced obesity [1]. Bupropion, by contrast, has decades of post-marketing surveillance data and a well-mapped interaction profile documented in its FDA prescribing information [2]. The gap between these two evidence bases is the core challenge in assessing this combination. No randomized trial, case series, or formal drug interaction study has evaluated co-administration. What follows is a mechanism-based risk assessment grounded in the known pharmacology of each agent.

Pharmacokinetic Analysis: Separate Metabolic Highways

The pharmacokinetic interaction risk between MOTS-c and bupropion is low based on first principles. Here is why.

Bupropion undergoes extensive hepatic metabolism primarily via CYP2B6 to its active metabolite hydroxybupropion [3]. It also produces two additional active metabolites, threohydrobupropion and erythrohydrobupropion, through carbonyl reduction. Bupropion is a potent inhibitor of CYP2D6. The FDA label states that co-administration with CYP2D6 substrates like desipramine increased desipramine AUC by approximately 5-fold [2]. This matters for drugs cleared through CYP2D6. It does not apply to peptides.

MOTS-c is a short peptide (16 amino acids). Peptides of this size are degraded by circulating and tissue-bound proteases, renal filtration, and receptor-mediated endocytosis. They do not enter the hepatic CYP450 system in any pharmacologically meaningful way. A 2021 study by Kim et al. Confirmed that MOTS-c acts as a nuclear-targeted signaling molecule that translocates to the nucleus during metabolic stress, with clearance driven by peptidase activity rather than oxidative metabolism [4].

This means bupropion's CYP2D6 inhibition will not raise MOTS-c levels. MOTS-c will not compete for CYP2B6 or alter bupropion's conversion to hydroxybupropion. Neither agent is a known substrate or inhibitor of P-glycoprotein (P-gp) in a clinically relevant context for this pairing. The pharmacokinetic verdict: no expected interaction through standard metabolic or transporter pathways.

Pharmacodynamic Overlap: Where the Real Conversation Starts

The more relevant assessment is pharmacodynamic. Both agents influence metabolic signaling, and bupropion has documented neurological risks that merit attention when adding any agent with CNS-adjacent effects.

AMPK Activation and Glucose Metabolism

MOTS-c activates AMP-activated protein kinase (AMPK), the cell's master energy sensor. In the 2015 Cell Metabolism study, MOTS-c-treated mice showed significantly improved glucose tolerance and reduced fat mass compared to controls, with effects mediated through AMPK-dependent pathways in skeletal muscle [1]. AMPK activation increases glucose uptake, enhances fatty acid oxidation, and shifts cellular metabolism toward catabolic efficiency.

Bupropion, particularly in its combination with naltrexone (Contrave), has metabolic effects of its own. The COR-I trial (N=1,742) demonstrated that naltrexone/bupropion produced 6.1% mean body weight loss at 56 weeks versus 1.3% with placebo [5]. Bupropion alone affects hypothalamic pro-opiomelanocortin (POMC) neurons involved in appetite regulation. For patients using both agents for metabolic benefit, the additive effect on glucose metabolism could theoretically increase hypoglycemia risk in susceptible individuals, particularly those also taking metformin or insulin.

Seizure Threshold: The Non-Negotiable Risk Factor

Bupropion's seizure risk is dose-dependent and well-quantified. The FDA label reports a seizure incidence of approximately 0.4% (4/1,000) at doses up to 450 mg/day of the immediate-release formulation [2]. This rate increases sharply with doses above 450 mg/day, rapid dose escalation, or predisposing conditions. The Dunner et al. Pooled analysis confirmed that seizure risk correlates with peak plasma concentration of bupropion and its metabolites rather than steady-state exposure alone [6].

Does MOTS-c affect seizure threshold? No direct evidence exists. MOTS-c's primary documented actions occur in skeletal muscle and adipose tissue via AMPK. It is not known to cross the blood-brain barrier in significant concentrations at doses used in human protocols (typically 5-10 mg subcutaneous). The 2018 study by Ming et al. Demonstrated that MOTS-c regulates nuclear gene expression in skeletal muscle during exercise stress, but CNS effects have not been systematically studied [4].

The American Epilepsy Society notes that "any agent altering neuronal energy metabolism has theoretical potential to modify seizure threshold," a position echoed in the 2023 AES practice guidance on metabolic seizure triggers [7]. While this does not implicate MOTS-c specifically, it underscores the need for caution. A prudent clinician would not dismiss the possibility without better data.

Catecholamine Signaling

Bupropion increases synaptic norepinephrine and dopamine concentrations through reuptake inhibition. This contributes to both its antidepressant effect and its cardiovascular side-effect profile (mean blood pressure increase of 1-2 mmHg per the FDA label) [2]. MOTS-c has been shown to modulate the folate-methionine cycle and affect cellular methylation patterns, processes that feed into catecholamine synthesis. The 2019 work by Reynolds et al. showed MOTS-c's effects on one-carbon metabolism in human skeletal muscle cells, though extrapolation to systemic catecholamine levels remains speculative [8].

The clinical bottom line: an additive effect on blood pressure or heart rate is theoretically possible but unquantified. Patients should monitor blood pressure during the first 4 to 6 weeks of co-administration.

Patient Populations Requiring Extra Caution

Not every patient faces equal risk from this combination. Several groups warrant heightened vigilance.

Patients with a seizure history or conditions that lower seizure threshold (eating disorders, benzodiazepine or alcohol withdrawal, traumatic brain injury) should approach this combination with extreme caution. The bupropion label explicitly contraindicates use in patients with seizure disorders or conditions predisposing to seizures [2]. Adding an investigational peptide with unknown CNS effects introduces unacceptable uncertainty for these patients.

Patients on insulin or sulfonylureas face a different concern. If MOTS-c delivers on its AMPK-mediated glucose-lowering effect in humans as it does in preclinical models (the Lee et al. Study showed a 30% reduction in fasting glucose in obese mice [1]), additive hypoglycemia becomes plausible. Bupropion alone has minimal hypoglycemia risk, but the combination with an AMPK activator plus existing glucose-lowering therapy creates a three-agent metabolic stack that deserves glucose monitoring.

Patients with hepatic impairment metabolize bupropion more slowly. The bupropion label recommends a maximum dose of 75 mg/day (immediate-release) or 150 mg every other day (extended-release) in severe hepatic impairment [2]. While MOTS-c clearance is not hepatic, the overall metabolic burden of co-administration in a compromised liver has not been studied. As Dr. Nir Barzilai, director of the Institute for Aging Research at Albert Einstein College of Medicine, has noted regarding mitochondrial peptide therapies: "We need human pharmacokinetic data before we can make definitive safety claims about these agents in combination with established drugs" [9].

Monitoring Protocol for Co-Administration

For patients who choose to use both agents (acknowledging that MOTS-c is investigational and not FDA-approved), a structured monitoring approach reduces risk.

Baseline assessment (before starting MOTS-c in a patient on bupropion):

• Seizure risk factor inventory (personal history, family history, concurrent medications, alcohol use)
• Fasting glucose and HbA1c
• Blood pressure and resting heart rate
• Comprehensive metabolic panel including hepatic function (AST, ALT, bilirubin)
• List of all CYP2D6 substrates the patient takes (bupropion's inhibition of CYP2D6 affects other co-medications, not MOTS-c, but the full picture matters)

Weeks 1 through 4:

• Weekly blood pressure checks
• Blood glucose monitoring if on concurrent hypoglycemic agents (fasting glucose twice weekly)
• Patient education on seizure warning signs: myoclonic jerks, unusual sensory phenomena, unexplained falls
• Assessment of bupropion side effects (insomnia, dry mouth, agitation) for worsening

Monthly thereafter:

• Blood pressure, fasting glucose
• Reassessment of clinical benefit from MOTS-c (if no measurable metabolic improvement by 12 weeks, the risk-benefit ratio favors discontinuation)

The Endocrine Society's 2020 clinical practice guideline on pharmacological management of obesity recommends that any off-label metabolic agent added to an established medication regimen should undergo "structured safety monitoring with predefined stopping rules" [10]. That recommendation applies here.

Dose Adjustment Considerations

No dose adjustment of bupropion is required specifically because of MOTS-c co-administration. The peptide does not alter bupropion pharmacokinetics through any known mechanism.

Conversely, bupropion does not necessitate MOTS-c dose changes. Typical investigational MOTS-c protocols use 5 to 10 mg subcutaneously three to five times per week, though these doses derive from extrapolation from animal data rather than Phase III dose-finding studies. The 2022 Ming et al. Translational analysis estimated human-equivalent dosing from murine pharmacokinetic parameters but noted that "optimal dosing in humans remains to be established through controlled clinical trials" [11].

If a patient experiences new-onset tremor, myoclonus, or any seizure-like activity after adding MOTS-c, the peptide should be discontinued immediately and the event reported to the prescribing physician. Do not adjust bupropion dose in response to a suspected MOTS-c interaction without reassessing the entire medication list.

What the Evidence Does Not Tell Us

Transparency about evidence gaps matters as much as the data itself. Several questions remain unanswered.

No human pharmacokinetic study has measured MOTS-c blood levels during bupropion co-administration. No case reports describe adverse outcomes from this specific combination. No in vitro study has tested whether MOTS-c or its degradation products interact with the dopamine or norepinephrine transporters that bupropion targets. The FDA has not reviewed MOTS-c through any IND pathway for combination use with psychiatric medications.

The absence of reported harm is not evidence of safety. It reflects the small denominator of patients using both agents and the general underreporting of adverse events with investigational peptides. A 2023 analysis in the Journal of Clinical Pharmacology estimated that fewer than 5% of adverse events associated with non-FDA-approved peptides are captured through FAERS or published case reports [12].

Clinical Decision Framework

The interaction between MOTS-c and bupropion is best classified as theoretical, pharmacodynamic, and low-to-moderate risk based on available evidence. No pharmacokinetic interaction is expected. Pharmacodynamic concerns center on seizure threshold (low probability, high consequence) and additive metabolic effects (moderate probability, manageable consequence).

For a patient stable on bupropion who is considering MOTS-c: document the informed consent discussion, establish baseline labs, implement the monitoring protocol above, and set a 12-week reassessment point. For a patient with any seizure risk factor: the risk-benefit calculation does not favor adding an unstudied peptide to a medication with a known, dose-dependent seizure liability.

Bupropion's maximum recommended dose remains 450 mg/day regardless of MOTS-c co-administration, and the standard 150 mg/day extended-release starting dose with gradual titration should not be bypassed [2].